


At Risk 228 87 24 3 Events 0 103 148 165




At Risk	138	44	13	2
Events	0	76	103	112

Female


Male

At Risk	90	43	11	1
Events	0	27	45	53

ırviva	Survival time, months				
omatic n	_	Male, In bed <50% of the day	Female, Asymptomatic		— Fer
	Male, Asym	nptomatic			
At Risk		18	6	1	
Events	0	13	24	28	
	Male, Sym _l	ptomatic and ambulatory			
At Risk	71	20	5	1	
Events	0	39	51	54	
r	Male, In be	ed <50% of the day			
At Risk	29	6	2	0	
Events	0	22	26	28	
1	Male, In be	ed > 50% of the day			
At Risk	1	0	0	0	
Events	0	1	1	1	
r	Female, As	symptomatic			
At Risk	27	13	2	0	
Events	0	4	8	9	
i	Female, Sy	mptomatic and ambulatory			
At Risk	42	23	8	1	
Events	0	12	22	28	
	Female, In	bed <50% of the day			
At Risk	21	7	1	0	
Events	0	11	15	16	



At Risk 228 87 24 3 CUM EVENTS 0 103 148 165



IVIGIO	i Ciliaic


At Risk	138	44	13	2
CUM EVENTS	0	76	103	112

Female


Male

At Risk	90	43	11	1
CUM EVENTS	0	27	45	53

ırvivə		Survival	time, months	
mptomatic n _l	Male, In bed	<50% of the day	— Female, Asymptomatic	
	Male, Asymptomatic			
At Risk	36	18	6	1
CUM EVENTS	0	13	24	28
	Male, Symptomatic a	nd ambulatory		
At Risk	71	20	5	1
CUM EVENTS	0	39	51	54
	Male, In bed <50% of	the day		
At Risk	29	6	2	0
CUM EVENTS	0	22	26	28
	Male, In bed > 50% o	f the day		
At Risk	1	0	0	0
CUM EVENTS	0	1	1	1
	Female, Asymptomat	ic		
At Risk	27	13	2	0
CUM EVENTS	0	4	8	9
	Female, Symptomatic	and ambulatory		
At Risk	42	23	8	1
CUM EVENTS	0	12	22	28
	Female, In bed <50%	of the day		
At Risk	21	7	1	0
CUM EVENTS	0	11	15	16



CUM EVENTS	228	87	24	3
N RISK	0	103	148	165



— Male — Female


CUM EVENTS	138	44	13	2
N RISK	0	76	103	112

Female

Male

CUM EVENTS	90	43	11	1
N RISK	0	27	45	53

ırvivə		Survival	time, months	
mptomatic n _l	— Male, In bed	d <50% of the day	— Female, Asymptomatic	_
	Male, Asymptomatic	:		
CUM EVENTS	36	18	6	1
N RISK	0	13	24	28
	Male, Symptomatic	and ambulatory		
CUM EVENTS	71	20	5	1
N RISK	0	39	51	54
	Male, In bed <50%	of the day		
CUM EVENTS	29	6	2	0
N RISK	0	22	26	28
	Male, In bed > 50%	of the day		
CUM EVENTS	1	0	0	0
N RISK	0	1	1	1
	Female, Asymptoma	atic		
CUM EVENTS	27	13	2	0
N RISK	0	4	8	9
	Female, Symptomat	ic and ambulatory		
CUM EVENTS	42	23	8	1
N RISK	0	12	22	28
	Female, In bed <509	% of the day		
CUM EVENTS	21	7	1	0
N RISK	0	11	15	16




Male

At Risk	138	44	13	2
Events	0	76	103	112


Female

At Risk	90	43	11	1
Events	0	27	45	53


ırviva		Survival	time, months		
omatic n	_	Male, In bed <50% of the day	Female, Asymptomatic		— Fer
	Male, Asym	nptomatic			
At Risk		18	6	1	
Events	0	13	24	28	
	Male, Sym _l	ptomatic and ambulatory			
At Risk	71	20	5	1	
Events	0	39	51	54	
r	Male, In be	ed <50% of the day			
At Risk	29	6	2	0	
Events	0	22	26	28	
1	Male, In be	ed > 50% of the day			
At Risk	1	0	0	0	
Events	0	1	1	1	
r	Female, As	symptomatic			
At Risk	27	13	2	0	
Events	0	4	8	9	
i	Female, Sy	mptomatic and ambulatory			
At Risk	42	23	8	1	
Events	0	12	22	28	
	Female, In	bed <50% of the day			
At Risk	21	7	1	0	
Events	0	11	15	16	




At Risk 228 87 24 3 Events 0 103 148 165



At Risk 227 87 24 3 Events 0 102 147 218







	3					
At Risk	98	97	94	83	61	0
Events	0	0	2	7	17	24
Ī	Orug B					
At Risk	102	102	95	75	55	0

Events

<u>_</u>						
Cumulative In	0	5	10	15	20	25
ula	-	-	Months to Dea		-	
Шņ						
O		_	Drug A, I — Drug	g A, II — Drug A	A, III	
		_	Drug B, I — Drug	g B, II — Drug E	3, III	
ı	Drug A, I					
At Risk	35	35	35	30	22	0
Events	0	0	0	4	7	9
ļ	Drug B, I					ļ
At Risk	33	33	33	28	23	0
Events	0	0	0	3	5	9
,	Drug A, II					
At Risk	32	32	30	27	23	0
Events	0	32 0	30 1	2	23 3	5
LVOIRO	O	C	,	-	J	
1	Drug B, II					
At Risk	36	36	32	23	17	0
Events	0	0	2	8	12	12
1	Drug A, III					
	_	20	20	00	40	0
At Risk	31 0	30 0	29 1	26 1	16 7	0 10
Events	U	U	1	1	1	10
Ī	Drug B, III					
At Risk	33	33	30	24	15	0
Events	0	0	2	6	9	12






— Drug A — Drug I

Drug A

At Risk	98	97	94	83	61	0
CUM EVENTS	0	0	2	7	17	24
Г	Drug B					

At Risk	102	102	95	75	55	0
CUM EVENTS	0	0	4	17	26	33

<u></u>						
± € : €	0	5	10	15	20	25
<u>a</u>	•		ths to Death/C			
Cumulative In						
O		— Drug A,	I — Drug A, II	— Drug A, III		
		— Drug B,	I — Drug B, II	— Drug B, III		
ı	Drug A, I					
At Risk	35	35	35	30	22	0
CUM EVENTS	0	0	0	4	7	9
ļ	Drug B, I					
At Risk	33	33	33	28	23	0
CUM EVENTS	0	0	0	3	5	9
ı	Drug A, II					
At Risk	32	32	30	27	23	0
CUM EVENTS	0	0	1	2	3	5
I	Drug B, II					
At Risk	36	36	32	23	17	0
CUM EVENTS	0	0	2	8	12	12
	5 4 111					
	Drug A, III					
At Risk	31	30	29	26	16	0
CUM EVENTS	0	0	1	1	7	1(
1	Drug B, III					
At Risk	33	33	30	0.4	45	0
CUM EVENTS	0	0	2	24 6	15 9	12
CONILVENTS	O	U	2	O	9	12




	-					
At Risk	98	97	94	83	61	0
Events	0	0	2	7	17	24
Г	Drug B					
		400	0.5	75		0
At Risk	102	102	95	75	55	()


Events

Cumulative Ir	0		Months to Dea	J A, II — Drug A		25
			Drug B, I — Drug	B, II — Drug E	3, 111	
	Drug A, I					
At Risk	35	35	35	30	22	0
Events	0	0	0	4	7	9
С	Drug B, I					
At Risk	33	33	33	28	23	0
Events	0	0	0	3	5	9
	Orug A, II					
At Risk	32	32	30	27	23	0
Events	0	0	1	2	3	5
	Orug B, II					
At Risk	36	36	32	23	17	0
Events	0	0	2	8	12	12
	Drug A, III					
At Risk	31	30	29	26	16	0
Events	0	0	1	1	7	10
0	Orug B, III					
At Risk	33	33	30	24	15	0
Events	0	0	2	6	9	12

⊏



At Risk	200	199	189	158	116	0
Events	0	0	6	24	43	57



At Risk	200	199	189	158	116	0
Events	0	0	6	24	43	57

